Hormone Therapy vs Surgery in HR Positive Breast Cancer

Hormone receptor positive breast cancer is driven by active oestrogen or progesterone receptors on the cancer cell surface. Surgery removes the primary tumour and achieves local disease control. Hormone therapy blocks the receptor pathway that sustains tumour growth, given either before surgery to reduce tumour volume or after surgery for five to ten years to lower recurrence risk. Both treatments address different aspects of the same disease and are sequenced in most HR positive cases rather than chosen between.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Surgery removes the disease. Hormone therapy stops it returning. Both have different jobs in the same treatment plan and one doesn’t replace the other.”

Giving hormone therapy before surgery is applied when tumour volume makes immediate surgery technically difficult or when downsizing the primary lesion changes what operation is feasible.

• Shrinking Before Operating: Aromatase inhibitors or tamoxifen over three to six months reduce primary tumour size and breast cancer treatment teams use this regularly to convert mastectomy cases into lumpectomy cases where adequate tumour downstaging is achieved with hormonal blockade alone.
• Specific Patient Profile Fits Best: Post-menopausal women with large HR positive, HER2 negative, low-grade tumours show the most predictable response, and for this particular group neoadjuvant hormone therapy is clinically sound over chemotherapy without the systemic toxicity chemotherapy carries.
• Slow Monitoring Across Months: Assessment runs at three to four monthly imaging intervals rather than a fixed short-course endpoint, which is structurally different from chemotherapy tracking and requires consistent patient engagement across the full treatment window.
• Adjuvant Hormone Therapy Always Follows Regardless: Five to ten years of adjuvant tamoxifen or aromatase inhibitor is standard in most HR positive cases after surgery, given the established late recurrence risk this subtype carries well beyond the initial treatment period.

Neoadjuvant hormone therapy modifies what operation becomes feasible. The operation itself stays in every curative plan.

• No Hormonal Regimen Removes Surgery From the Plan: Hormone therapy doesn’t eliminate the surgical requirement in operable HR positive breast cancer and robotic cancer surgery or conventional lumpectomy or mastectomy stays in every curative pathway regardless of receptor status or prior hormonal treatment response.
• Oncotype DX Takes Chemotherapy Out for Low-Risk Patients: Genomic testing identifies HR positive patients where hormone therapy alone after surgery matches chemotherapy plus hormone therapy in long-term survival, removing chemotherapy from the treatment plan entirely for this specific group.
• Extensive Nodal Disease Still Goes to Chemotherapy: Large tumours, multiple positive nodes or high genomic risk scores mean neoadjuvant chemotherapy rather than hormone therapy before surgery, because cytotoxic response speed matters more than what hormonal blockade alone can achieve in this setting.
• Pre-Menopausal High-Risk Cases Get Ovarian Suppression Added: Combining ovarian suppression with aromatase inhibitor therapy in pre-menopausal high-risk HR positive patients produces better disease-free survival than tamoxifen monotherapy in this defined subgroup, and is now a standard recommendation rather than an optional escalation.

Treatment sequencing in HR positive breast cancer is decided at tumour board and for more on neoadjuvant treatment options in breast cancer, our blog on neoadjuvant chemotherapy covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to every HR positive breast cancer case including sequencing decisions between neoadjuvant hormone therapy, chemotherapy and surgery. He heads Oncology Services across Karnataka and leads breast cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT and over 25 published clinical studies. Patients needing clarity on their HR positive treatment sequence are assessed here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Hormone Receptor Positive Breast Cancer
2. World Health Organization — Breast Cancer Treatment

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.